



- (51) **International Patent Classification:**
C07K 16/28 (2006.01) A61P 35/04 (2006.01)
A61P 35/00 (2006.01)
- (21) **International Application Number:**
PCT/IB2024/059994
- (22) **International Filing Date:**
11 October 2024 (11.10.2024)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
PCT/CN2023/124264
12 October 2023 (12.10.2023) CN
PCT/CN2023/135545
30 November 2023 (30.11.2023) CN
- (71) **Applicant: BEIGENE SWITZERLAND GMBH**
[CH/CH]; Aeschengraben 27, 4051 Basel (CH).
- (72) **Inventors: ZHENG, Wenjuan;** No. 30 Science Park Road, Zhongguancun Life Science Park, Changping District, Beijing, Beijing 102206 (CN). **WANG, Ruihua;** 2F, Building A, No. 51 Rijiang Road, China (Shanghai) Pilot Free Trade Zone, Shanghai, Shanghai 200131 (CN). **ZHANG, Qiuyang;** 2F, Building A, No. 51 Rijiang Road, China (Shanghai) Pilot Free Trade Zone, Shanghai, Shanghai 200131 (CN).

(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

(54) **Title:** ANTI-PD-1-BASED TREATMENT BEFORE AND AFTER SURGERY




FIG. 1

(57) **Abstract:** The disclosure relates to treatment of solid cancers, such as breast, colon and lung cancer (in particular, non-small cell lung cancer (NSCLC)) in human subjects with an anti-PD-1 antibody as monotherapy or as combination therapy with for example chemotherapy and/or surgery. The provided treatment may be Tislelizumab in combination with chemotherapy prior to surgery, with a different dose of Tislelizumab in the adjuvant phase following surgery. The administration regimen may include administration of 200 mg of an anti-PD-1 antibody (e.g., tislelizumab) (e.g., every three weeks), followed by tumor resection, and administration of 400 mg of the anti-PD-1 antibody (e.g., every six weeks). Furthermore, the chemotherapy may be platinum-based (e.g., carboplatin and/or cisplatin), and may further include pemetrexed (e.g., for non-squamous carcinoma) or paclitaxel (e.g., for squamous carcinoma).

[Continued on next page]

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*